ARCA biopharma Inc.  (ABIO) Trade Now »     Rate ABIO  -  Discuss ABIO  -  Add to Watch List        

Below are 13 companies with market caps below $200M which have pending new drug product decisions with the FDA that are expected to have a major impact on each of the underlying stock prices as the PDUFA decision dates approach and the decision is ultimately announced. A high risk/reward trading approach to consider for speculative traders is investing a small amount of money that you can afford to lose in a basket of stocks included in <font> Extreme FDA and Clinical Trial Calendar Trades </font> , which are highlighted in periodic articles at BioMedReports.com .

 

 

Heart failure has always been one of the predominant fatal human conditions, today I focus on a company which has developed a treatment with encouraging results against this, often fatal, disease.

 

Key Facts : Heart failure becomes more common with increasing age. About 1 in 35 people aged 65-74 years have heart failure. This increases to about 1 in 15 of people aged 75-84 years, and to just over 1 in 7 people aged 85 years and above. It is uncommon in younger people.

 

Below are 12 companies with market caps below $200M which have pending new drug product decisions at the FDA that are expected to have a major impact on each of the underlying stock prices as the PDUFA decision dates approach and the decision is ultimately announced.

 

BioMedReports.com FDA Calendar:

http://biomedreports.com/fda-calendar.html

 

FDA Decision Calendar: 16 Extreme Trades

 

By Mike Havrilla on 2/4/09

ETF Innovators

 

Click here for a link to my previous FDA calendars and the list below highlights 16 companies with pending new product decisions at the agency + market caps below $150M, making them ideal candidates for extreme stock price volatility trades.

 

http://www.etfinnovators.com/2009/02/fda-decision-calendar-16...

 

Updated Clinical Trial and FDA Calendar

 

The tables at my website link below feature an updated calendar of 78 expected FDA new product decisions and 92 pending clinical trial result estimates + pending FDA re-submissions or new submissions for regulatory approval. Click here for a link to my previous calendars and below is a summary of FDA and clinical trial news since my last article.

 

http://www.etfinnovators.com/2009/01/updated-clinical-trial-a...